Cargando…

Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients

BACKGROUND: Compared to the general population, cancer patients are at higher risk of morbidity and mortality following SARS‐CoV‐2 infection. The immune response to a two‐dose regimen of mRNA vaccines in cancer patients is generally lower than in immunocompetent individuals. Booster doses may meanin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giuliano, Anna, Kuter, Barbara, Pilon‐Thomas, Shari, Whiting, Junmin, Mo, Qianxing, Leav, Brett, Sirak, Bradley, Cubitt, Christopher, Dukes, Christopher, Isaacs‐Soriano, Kimberly, Kennedy, Kayoko, Ball, Somedeb, Dong, Ning, Jain, Akriti, Hwu, Patrick, Lancet, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354405/ https://www.ncbi.nlm.nih.gov/pubmed/37377402 http://dx.doi.org/10.1002/cac2.12453

Ejemplares similares

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
por: Giuliano, Anna R., et al.
Publicado: (2022)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Long-Term CD4(+) T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study
por: Gallen, Corey, et al.
Publicado: (2022)

SARS-CoV-2 antibody response duration and neutralization following natural infection
por: Dukes, Christopher W, et al.
Publicado: (2023)

SARS-CoV-2 Period Seroprevalence and Related Factors, Hillsborough County, Florida, USA, October 2020–March 2021
por: Giuliano, Anna R., et al.
Publicado: (2022)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

Methylation of HPV16 and EPB41L3 in oral gargles and the detection of early and late oropharyngeal cancer
por: Dickey, Brittney L., et al.
Publicado: (2022)

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine
por: Chu, Laurence, et al.
Publicado: (2021)

Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
por: El Sahly, Hana M, et al.
Publicado: (2022)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
por: Chalkias, Spyros, et al.
Publicado: (2022)

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273)
por: Leav, Brett, et al.
Publicado: (2022)

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
por: Oosting, Sjoukje F, et al.
Publicado: (2022)

P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
por: Aguirre, Luis E., et al.
Publicado: (2023)

Association of Patient-Reported Physical Activity on Allogeneic Hematopoietic Cell Transplant Outcomes
por: Jayani, Reena V., et al.
Publicado: (2021)

Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
por: Ali, Kashif, et al.
Publicado: (2021)

Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary
por: Tré-Hardy, Marie, et al.
Publicado: (2021)

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
por: van Leeuwen, Leanne P.M., et al.
Publicado: (2022)

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS
por: Naficy, A., et al.
Publicado: (2023)

Immediate triggering of 4-1BB co-stimulation during initiation of tumor-infiltrating lymphocyte (TIL) expansion from melanoma tumors accelerates CD8+ T-cell outgrowth and tumor specificity
por: Chacon, Jessica, et al.
Publicado: (2013)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
por: Huang, Szu-Ting, et al.
Publicado: (2023)

Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
por: Baden, Lindsey R., et al.
Publicado: (2021)

Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Jiménez, Moraima, et al.
Publicado: (2022)

Immunogenicity and Safety of the Third Booster Dose with mRNA-1273 COVID-19 Vaccine after Receiving Two Doses of Inactivated or Viral Vector COVID-19 Vaccine
por: Tangsathapornpong, Auchara, et al.
Publicado: (2023)

Immunogenicity and safety of homologous and heterologous ChAdOx1-S and mRNA-1273 vaccinations in healthy adults in Taiwan
por: Kang, Chun-Min, et al.
Publicado: (2022)

Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
por: Hoshina, Yoji, et al.
Publicado: (2022)

112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents
por: Muñoz, F. Longo, et al.
Publicado: (2021)

Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination
por: Jongkees, Marlou J, et al.
Publicado: (2022)

Oral secretory leukocyte protease inhibitor (SLPI): Associations with oropharyngeal cancer and treatment outcome
por: Dickey, Brittney L., et al.
Publicado: (2021)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
por: Baden, Lindsey R., et al.
Publicado: (2020)

Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
por: Hall, Victoria G., et al.
Publicado: (2021)

Acute myocarditis after the third dose of COVID‐19 mRNA‐1273 vaccine
por: Yamada, Takayuki
Publicado: (2023)

Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial
por: Pajon, Rolando, et al.
Publicado: (2022)

Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines
por: Naranbhai, Vivek, et al.
Publicado: (2021)

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial
por: Naficy, Abdi, et al.
Publicado: (2023)

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
por: Anderson, Evan J., et al.
Publicado: (2022)

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
por: Chu, Laurence, et al.
Publicado: (2022)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age
por: Otten, Gillis, et al.
Publicado: (2018)

Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial
por: Janssen, Cécile, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t8o0hgvjhh99k504qvhk1lv1s9